Osivax Licenses GC FLU Rights Outside Japan And Korea, Advancing A Single-Shot Flu Combination Plan

Osivax has licensed rights to GC Biopharma’s GC FLU vaccine outside of Japan and Korea, giving the French biotech a path to develop a combination influenza shot built around its own candidate, OVX836. Under the agreement, Osivax will lead development and commercialization of the combination vaccine outside of Korea, while GC Biopharma will supply its vaccine and receive royalties.

The strategy is to combine two different immunologic approaches in one product. OVX836 is an influenza A vaccine candidate targeting nucleoprotein, a highly conserved internal antigen, while GC FLU is an inactivated seasonal influenza vaccine designed to induce antibody responses against hemagglutinin surface antigens from A and B forms of the virus.

Why Osivax Wants A Combination Product

The company’s rationale comes from the limits of standard seasonal flu vaccines. Conventional products target surface proteins that change over time, forcing seasonal updates and still only partially matching circulating strains in some years. Osivax’s bet is that adding a T-cell response against the more conserved NP antigen could broaden protection against influenza A beyond what a traditional shot can do on its own.

That idea already has some clinical support from combination studies using GSK’s Fluarix Tetra. In a phase 2a trial in 60 healthy volunteers, Osivax said the data suggested synergistic immune responses and broader cross-protection. The company also tested the combination in a larger phase 2 study.

The Commercial Signal

So far, participants in those studies received OVX836 and Fluarix Tetra as separate injections. Osivax’s move to license GC FLU reflects a practical commercial judgment as much as a scientific one: if two injections discourage uptake, especially among people afraid of needles, the immunology case may not translate into vaccination rates. A single-shot formulation is therefore not just a convenience play but part of the product thesis.

The deal is non-exclusive, and Osivax’s rights exclude Japan and Korea. Even with those geographic limits, the agreement gives the biotech a clearer route to convert earlier combination data into a proprietary product candidate rather than relying on co-administration with another company’s marketed vaccine.